Ngenla is an injection of long-acting growth hormone, administered once a week, for children 3 years and older with growth hormone deficiency. It helps support normal growth using a prefilled pen system.
Approval Date
27-Jun-23
Data Exclusivity Expiry
27-Jun-27
Market Exclusivity Expiry
27-Jun-35
Commercial snapshot
Market performance & projections
Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
128
2027
155
2028
193
2029
230
2030
260
2031
292
2032
317
Molecule profile
Details & specifications
Molecule
Somatrogon-Ghla
Innovator
OPKO/PFIZER
Dosage Form
Prefilled Injection
Strength
24 mg and 60 mg
Therapeutic Category
Hormonal Therapy
Usage
To treat growth failure due to inadequate secretion of endogenous growth hormone
Good to know
Frequently asked questions
Ready to act on this opportunity?
Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.